The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain

Neuroscience

Volumn 164, Issue 4, 2009, Pages 1754-1763

  Han, M ^a,b   Huang, X F ^a,b   du Bois, T M ^a,b   Deng, C ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

5 HT1A receptor; amygdala; antipsychotic drugs; cingulate cortex; hippocampus; schizophrenia

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN 1A RECEPTOR;

ADAPTATION; AMYGDALOID NUCLEUS; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CINGULATE GYRUS; CONTROLLED STUDY; DESENSITIZATION; FEMALE; HIPPOCAMPUS; LIMBIC SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; SCHIZOPHRENIA; SYMPTOM; TREATMENT DURATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BINDING SITES; FEMALE; HALOPERIDOL; LIMBIC SYSTEM; PIPERAZINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN, 5-HT1; RNA, MESSENGER;

EID: 70449530704     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.09.041     Document Type: Article

References (55)

1. Aravagiri M., Teper Y., and Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20 (1999) 369-377
2. Arjona A.A., Zhang S.X., Adamson B., and Wurtman R.J. An animal model of antipsychotic-induced weight gain. Behav Brain Res 152 (2004) 121-127
3. Ase A.R., Amdiss F., Hebert C., Huang N., van Gelder N.M., and Reader T.A. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. J Neural Transm 106 (1999) 75-105
4. Bantick R.A., Deakin J.F., and Grasby P. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. J Psychopharmacol 15 (2001) 37-46
5. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
6. Blier P., and Ward N.M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol Psychiatry 53 (2003) 193-203
7. Burnet P.W., Chen C.P., McGowan S., Franklin M., and Harrison P.J. The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 73 (1996) 531-540
8. Burnet P.W., Eastwood S.L., and Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15 (1996) 442-455
9. Burnet P.W., Eastwood S.L., and Harrison P.J. [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30 (1997) 565-574
10. Csernansky J.G., Wang L., Jones D., Rastogi-Cruz D., Posener J.A., Heydebrand G., Miller J.P., and Miller M.I. Hippocampal deformities in schizophrenia characterized by high dimensional brain mapping. Am J Psychiatry 159 (2002) 2000-2006
11. Dean B., Tomaskovic-Crook E., Opeskin K., Keks N., and Copolov D. No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem Int 34 (1999) 109-115
12. DeLeon A., Patel N.C., and Lynn Crismon M. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26 (2004) 649-666
13. Diaz-Mataix L., Scorza M.C., Bortolozzi A., Toth M., Celada P., and Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25 (2005) 10831-10843
14. Dryden S., Wang Q., Frankish H.M., and Williams G. Differential effects of the 5-HT1B/2C receptor agonist mCPP and the 5-HT1A agonist flesinoxan on hypothalamic neuropeptide Y in the rat: evidence that NPY may mediate serotonin's effects on food intake. Peptides 17 (1996) 943-949
15. Frankle W.G., Lombardo I., Kegeles L.S., Slifstein M., Martin J.H., Huang Y., Hwang D.R., Reich E., Cangiano C., Gil R., Laruelle M., and Abi-Dargham A. Serotonin 1A receptor availability in patients with schizophrenia and schizoaffective disorder: a positron emission tomography imaging study with [11C]Way:100635. Psychopharmacology (Berl) 189 (2006) 155-164
16. Grunder G., Fellows C., Janouschek H., Veselinovic T., Boy C., Brocheler A., Kirschbaum K.M., Hellmann S., Spreckelmeyer K.M., Hiemke C., Rosch F., Schaefer W.M., and Vernaleken I. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. [see comment]. Am J Psychiatry 165 (2008) 988-995
17. Gurevich E.V., and Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42 (1997) 529-545
18. Hall H., Lundkvist C., Halldin C., Farde L., Pike V.W., McCarron J.A., Fletcher A., Cliffe I.A., Barf T., Wikström H., and Sedvall G. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res 745 (1997) 96-108
19. Han M., Deng C., Burne T.H., Newell K.A., and Huang X.F. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 33 (2008) 569-580
20. Han M., Huang X.-F., and Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol 12 (2009) 941-952
21. Han M., Newell K., Zavitsanou K., Deng C., and Huang X.F. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J Neurosci Res 86 (2008) 457-464
22. Hashimoto T., Nishino N., Nakai H., and Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48 (1991) 355-363
23. Huang X.-F., Han M., Huang X., Zavitsanou K., and Deng C. Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res 171 (2006) 355-362
24. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., and Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76 (2001) 1521-1531
25. Joyce J.N., and Gurevich E.V. Cortex and serotonin in schizophrenia: effects of antipsychotic treatment?. Schizophr Res 24 (1997) 33-34
26. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., and Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8 4 (1993) 315-336
27. Kapur S., and Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1081-1090
28. Kapur S., and Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153 (1996) 466-476
29. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305 (2003) 625-631
30. Keefe R.S.E., Young C.A., Rock S.L., Purdon S.E., Gold J.M., and Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81 (2006) 1-15
31. Kern R.S., Green M.F., Cornblatt B.A., Owen J.R., McQuade R.D., Carson W.H., Ali M., and Marcus R. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 187 (2006) 312-320
32. Khawaja X. Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist. Brain Res 673 (1995) 217-225
33. Knable M.B., Barci B.M., Bartko J.J., Webster M.J., and Torrey E.F. Abnormalities of the cingulate gyrus in bipolar disorder and other severe psychiatric illnesss: postmortem findings from the Stanley Foundation Neuropathology Consortium and literature review. Clin Neurosci Res 2 (2002) 171-181
34. Kreiss D.S., and Lucki I. Chronic administration of the 5-HT1A receptor agonist 8-OH-DPAT differentially desensitizes 5-HT1A autoreceptors of the dorsal and median raphe nuclei. Synapse 25 (1997) 107-116
35. Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493 (2004) 75-83
36. López-Alonso V.E., Mancilla-Díaz J.M., Rito-Domingo M., González-Hernández B., and Escartín-Pérez R.E. The effects of 5-HT1A and 5-HT2C receptor agonists on behavioral satiety sequence in rats. Neurosci Lett 416 (2007) 285-288
37. McClintock M.K. Estrous synchrony and its mediation by airborne chemical communication (Rattus norvegicus). Horm Behav 10 (1978) 264-275
38. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 (1999) 106S-115S
39. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13 (2008) 27-35
40. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., and Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31 (2006) 1854-1863
41. Nelson M.D., Saykin A.J., Flashman L.A., and Riordan H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry 55 (1998) 433-440
42. Park S., Harrold J.A., Widdowson P.S., and Williams G. Increased binding at 5-HT1A, 5-HT1B, and 5-HT2A receptors and 5-HT transporters in diet-induced obese rats. Brain Res 847 (1999) 90-97
43. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 3rd ed. (1997), Academic Press, San Diego, CA
44. Rajarethinam R., DeQuardo J.R., Miedler J., Arndt S., Kirbat R., Brunberg J.A., and Tandon R. Hippocampus and amygdala in schizophrenia: assessment of the relationship of neuroanatomy to psychopathology. Psychiatry Res 108 (2001) 79-87
45. Schank J.C. Do Norway rats (Rattus norvegicus) synchronize their estrous cycles?. Physiol Behav 72 (2001) 129-139
46. Sprouse J.S., and Aghajanian G.K. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 27 (1988) 707-715
47. Sumiyoshi C., Sumiyoshi T., Roy A., Jayathilake K., and Meltzer H.Y. Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. Int J Neuropsychopharmacol 9 (2006) 677-683
48. Sumiyoshi T., Matsui M., Yamashita I., Nohara S., Uehara T., Kurachi M., and Meltzer H.Y. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 20 (2000) 386-388
49. Sumiyoshi T., Park S., Jayathilake K., Roy A., Ertugrul A., and Meltzer H.Y. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 95 (2007) 158-168
50. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Dilley G.E., and Meltzer H.Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 708 (1996) 209-214
51. Vizi E.S., and Kiss J.P. Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions. [see comment]. Hippocampus 8 (1998) 566-607
52. Vogt B.A., Finch D.M., and Olson C.R. Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex 2 (1992) 435-443
53. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., and Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157 (2000) 16-25
54. Yasuno F., Suhara T., Ichimiya T., Takano A., Ando T., and Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 55 (2004) 439-444
55. Zavitsanou K., Katsifis A., Mattner F., and Huang X.-F. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29 (2004) 619-625